Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073515 · ClinicalTrials.gov registry record · Phase 2
Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices
A Phase 2 study, sponsored by ARCA Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT00073515 is a Phase 2 study that has completed, run by ARCA Biopharma. The registered enrollment target is 115 participants.
The verdict
NCT00073515, a Phase 2 study, has completed, sponsored by ARCA Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
This trial is for patients with a central venous catheter (a vascular access device) that is not functioning properly (unable to withdraw blood). The trial compares a new blood clot dissolving agent (alfimeprase) against the currently used treatment.
Interventions
- DRUG Alfimeprase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073515
The ClinicalTrials.gov registry entry for NCT00073515 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ARCA Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alfimeprase is the first listed.
NCT00073515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073515 about?
NCT00073515 is a clinical study titled "Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices". This trial is for patients with a central venous catheter (a vascular access device) that is not functioning properly (unable to withdraw blood). The trial compares a new blood clot dissolving agent (alfimeprase) against the currently used treatment.
What is the current status of trial NCT00073515?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants.
What interventions are being tested in trial NCT00073515?
The interventions under investigation include: Alfimeprase (DRUG).
Who is sponsoring clinical trial NCT00073515?
This trial is sponsored by ARCA Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.